{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T20:00:44Z","timestamp":1792612844854,"version":"4.5.0"},"reference-count":149,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T00:00:00Z","timestamp":1705968000000},"content-version":"am","delay-in-days":328,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NCI","doi-asserted-by":"publisher","award":["1K08CA230319"],"award-info":[{"award-number":["1K08CA230319"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008884","name":"Edward P. Evans Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008884","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.leukres.2023.107020","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T12:11:30Z","timestamp":1674216690000},"page":"107020","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms"],"prefix":"10.1016","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0745-7049","authenticated-orcid":false,"given":"Jacob","family":"Jahn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8638-9365","authenticated-orcid":false,"given":"Benjamin","family":"Diamond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3998-6167","authenticated-orcid":false,"given":"Jeffrey","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2094-6923","authenticated-orcid":false,"given":"Skye","family":"Montoya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tulasigeri M.","family":"Totiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ola","family":"Landgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Maura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4407-6325","authenticated-orcid":false,"given":"Justin","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.leukres.2023.107020_bib1","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.leukres.2023.107020_bib2","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1309\/NQ3PMV4U8YV39JWJ","article-title":"Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant","volume":"127","author":"Singh","year":"2007","journal-title":"Am. J. Clin. Pathol."},{"issue":"1","key":"10.1016\/j.leukres.2023.107020_bib3","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/S1470-2045(16)30626-X","article-title":"Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study","volume":"18","author":"Takahashi","year":"2017","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1016\/j.leukres.2023.107020_bib4","first-page":"2137","article-title":"The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML, blood","volume":"117","author":"Kayser","year":"2011","journal-title":"J. Am. Soc. Hematol."},{"issue":"5","key":"10.1016\/j.leukres.2023.107020_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-020-0323-4","article-title":"Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century","volume":"10","author":"Pulte","year":"2020","journal-title":"Blood Cancer J."},{"issue":"2","key":"10.1016\/j.leukres.2023.107020_bib6","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s00277-015-2547-0","article-title":"Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group","volume":"95","author":"L\u00fcbbert","year":"2016","journal-title":"Ann. Hematol."},{"issue":"24","key":"10.1016\/j.leukres.2023.107020_bib7","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1200\/JCO.2014.55.8361","article-title":"Cancer survivorship issues: life after treatment and implications for an aging population","volume":"32","author":"Rowland","year":"2014","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.leukres.2023.107020_bib8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.beha.2013.09.001","article-title":"The evolving challenge of therapy-related myeloid neoplasms","volume":"26","author":"Churpek","year":"2013","journal-title":"Best. Pract. Res. Clin. Haematol."},{"issue":"4","key":"10.1016\/j.leukres.2023.107020_bib9","first-page":"220","article-title":"Cancer treatment and survivorship statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA: a Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.leukres.2023.107020_bib10","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1158\/1055-9965.EPI-12-1356","article-title":"Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care","volume":"22","author":"De Moor","year":"2013","journal-title":"Cancer Epidemiol., Biomark. Prev."},{"key":"10.1016\/j.leukres.2023.107020_bib11","article-title":"SEER cancer statistics review, 1975\u20132010","author":"Howlader","year":"2014","journal-title":"Natl. Cancer Inst."},{"issue":"10","key":"10.1016\/j.leukres.2023.107020_bib12","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/ajh.21828","article-title":"Incidence of myelodysplastic syndromes within a nonprofit healthcare system in western Washington state, 2005\u20132006","volume":"85","author":"De Roos","year":"2010","journal-title":"Am. J. Hematol."},{"issue":"3","key":"10.1016\/j.leukres.2023.107020_bib13","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/ajh.23908","article-title":"Characterization and prognostic features of secondary acute myeloid leukemia in a population\u2010based setting: a report from the S wedish A cute L eukemia R egistry","volume":"90","author":"Huleg\u00e5rdh","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.leukres.2023.107020_bib14","unstructured":"S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele, J.W. Vardiman, 2008. WHO classification of tumours of haematopoietic and lymphoid tissues, International agency for research on cancer Lyon 2008."},{"key":"10.1016\/j.leukres.2023.107020_bib15","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.cbi.2005.03.023","article-title":"Therapy-related myeloid leukaemia: a model for leukemogenesis in humans","volume":"153","author":"Larson","year":"2005","journal-title":"Chem. -Biol. Interact."},{"issue":"1","key":"10.1016\/j.leukres.2023.107020_bib16","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2002-11-3343","article-title":"Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series","volume":"102","author":"Smith","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.leukres.2023.107020_bib17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1097\/MOH.0000000000000675","article-title":"Clonal hematopoiesis and myeloid malignancies: clonal dynamics and clinical implications","volume":"28","author":"Elena","year":"2021","journal-title":"Curr. Opin. Hematol."},{"issue":"6465","key":"10.1016\/j.leukres.2023.107020_bib18","doi-asserted-by":"crossref","first-page":"eaan4673","DOI":"10.1126\/science.aan4673","article-title":"Clonal hematopoiesis in human aging and disease","volume":"366","author":"Jaiswal","year":"2019","journal-title":"Science"},{"issue":"22","key":"10.1016\/j.leukres.2023.107020_bib19","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.leukres.2023.107020_bib20","first-page":"3616","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes, Blood","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"J. Am. Soc. Hematol."},{"issue":"25","key":"10.1016\/j.leukres.2023.107020_bib21","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.leukres.2023.107020_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of diffuse large B cell lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2023.107020_bib23","series-title":"Mayo Clinic Proceedings","first-page":"1122","article-title":"Clinical implications of clonal hematopoiesis","author":"Steensma","year":"2018"},{"issue":"26","key":"10.1016\/j.leukres.2023.107020_bib24","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.leukres.2023.107020_bib25","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/s41588-020-00710-0","article-title":"Cancer therapy shapes the fitness landscape of clonal hematopoiesis","volume":"52","author":"Bolton","year":"2020","journal-title":"Nat. Genet."},{"key":"10.1016\/j.leukres.2023.107020_bib26","series-title":"Clonal Hematopoiesis, Seminars In Hematology","first-page":"43","author":"Jan","year":"2017"},{"issue":"2","key":"10.1016\/j.leukres.2023.107020_bib27","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.stem.2018.01.011","article-title":"Clonal hematopoiesis and evolution to hematopoietic malignancies","volume":"22","author":"Bowman","year":"2018","journal-title":"Cell stem Cell"},{"key":"10.1016\/j.leukres.2023.107020_bib28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.exphem.2020.02.001","article-title":"Clonal hematopoiesis in cancer","volume":"83","author":"Park","year":"2020","journal-title":"Exp. Hematol."},{"issue":"3","key":"10.1016\/j.leukres.2023.107020_bib29","article-title":"Therapy-related clonal hematopoiesis in patients with non-hematologic cancers is common and associated with adverse clinical outcomes","volume":"21","author":"Coombs","year":"2017","journal-title":"Cell Atem Cell"},{"issue":"7","key":"10.1016\/j.leukres.2023.107020_bib30","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1002\/cncr.23325","article-title":"Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and\/or radiation","volume":"112","author":"Abdelhameed","year":"2008","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.leukres.2023.107020_bib31","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.clml.2014.03.001","article-title":"A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia","volume":"14","author":"Quint\u00e1s-Cardama","year":"2014","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"issue":"5","key":"10.1016\/j.leukres.2023.107020_bib32","first-page":"759","article-title":"Nonrandom chromosomal abnormalities in acute nonlymphocytic leukemia in patients treated for Hodgkin disease and non-Hodgkin lymphomas","volume":"50","author":"Rowley","year":"1977","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107020_bib33","doi-asserted-by":"crossref","unstructured":"H. Super, N.R. McCabe, M.J. Thirman, R.A. Larson, M.M. Le Beau, J. Pedersen-Bjergaard, P. Philip, M.O. Diaz, J.D. Rowley, 1993. Rearrangements of the MLL gene in therapy-related acute myeloid leukemia in patients previously treated with agents targeting DNA-topoisomerase II, (1993).","DOI":"10.1182\/blood.V82.12.3705.bloodjournal82123705"},{"issue":"1","key":"10.1016\/j.leukres.2023.107020_bib34","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/sj.leu.2403187","article-title":"Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML","volume":"18","author":"Schoch","year":"2004","journal-title":"Leukemia"},{"issue":"7584","key":"10.1016\/j.leukres.2023.107020_bib35","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature16166","article-title":"Substantial contribution of extrinsic risk factors to cancer development","volume":"529","author":"Wu","year":"2016","journal-title":"Nature"},{"issue":"7793","key":"10.1016\/j.leukres.2023.107020_bib36","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.leukres.2023.107020_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-17459-z","article-title":"Accelerated single cell seeding in relapsed multiple myeloma","volume":"11","author":"Landau","year":"2020","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.leukres.2023.107020_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-24858-3","article-title":"The evolution of hematopoietic cells under cancer therapy","volume":"12","author":"Pich","year":"2021","journal-title":"Nat. Commun."},{"issue":"14","key":"10.1016\/j.leukres.2023.107020_bib39","first-page":"1599","article-title":"Clonal hematopoiesis and risk for hematologic malignancy","volume":"136","author":"Warren","year":"2020","journal-title":"Blood"},{"issue":"14","key":"10.1016\/j.leukres.2023.107020_bib40","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1200\/JCO.2016.71.6712","article-title":"Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma","volume":"35","author":"Gibson","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.leukres.2023.107020_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-16805-5","article-title":"Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant","volume":"11","author":"Mouhieddine","year":"2020","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.leukres.2023.107020_bib42","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.leukres.2014.12.006","article-title":"Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases","volume":"39","author":"Ok","year":"2015","journal-title":"Leuk. Res."},{"issue":"7","key":"10.1016\/j.leukres.2023.107020_bib43","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.1073\/pnas.1324297111","article-title":"Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission","volume":"111","author":"Corces-Zimmerman","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7382","key":"10.1016\/j.leukres.2023.107020_bib44","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.leukres.2023.107020_bib45","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3324\/haematol.2012.076729","article-title":"Mutational analysis of therapy-related myelodysplastic syndromes and acute myelogenous leukemia","volume":"98","author":"Shih","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.leukres.2023.107020_bib46","doi-asserted-by":"crossref","unstructured":"M. Heuser, 2016. Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment?, Hematology 2014, the American Society of Hematology Education Program Book 2016(1) (2016) 24\u201332.","DOI":"10.1182\/asheducation-2016.1.24"},{"key":"10.1016\/j.leukres.2023.107020_bib47","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1097\/JOM.0b013e3181f73ae6","article-title":"Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs","author":"McDiarmid","year":"2010","journal-title":"J. Occup. Environ. Med."},{"issue":"6","key":"10.1016\/j.leukres.2023.107020_bib48","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1200\/JCO.1993.11.6.1039","article-title":"Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation","volume":"11","author":"Sandoval","year":"1993","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.leukres.2023.107020_bib49","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1038\/leu.2010.43","article-title":"A comparison of the cytogenetic alterations and global DNA hypomethylation induced by the benzene metabolite, hydroquinone, with those induced by melphalan and etoposide","volume":"24","author":"Ji","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2023.107020_bib50","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0165-4608(89)90076-9","article-title":"The chemotherapeutic drug melphalan induces breakage of chromosomes regions rearranged in secondary leukemia","volume":"37","author":"Mamuris","year":"1989","journal-title":"Cancer Genet. Cytogenet."},{"issue":"11","key":"10.1016\/j.leukres.2023.107020_bib51","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1038\/sj.leu.2404381","article-title":"Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia","volume":"20","author":"Pedersen-Bjergaard","year":"2006","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.leukres.2023.107020_bib52","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/sj.leu.2405078","article-title":"Genetics of therapy-related myelodysplasia and acute myeloid leukemia","volume":"22","author":"Pedersen-Bjergaard","year":"2008","journal-title":"Leukemia"},{"issue":"1\u20132","key":"10.1016\/j.leukres.2023.107020_bib53","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cbi.2009.12.013","article-title":"Incidence and susceptibility to therapy-related myeloid neoplasms","volume":"184","author":"Leone","year":"2010","journal-title":"Chem. -Biol. Interact."},{"issue":"6","key":"10.1016\/j.leukres.2023.107020_bib54","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.3390\/ijerph9062075","article-title":"Mechanism of generation of therapy related leukemia in response to anti-topoisomerase II agents","volume":"9","author":"Cowell","year":"2012","journal-title":"Int. J. Environ. Res. Public Health"},{"issue":"5","key":"10.1016\/j.leukres.2023.107020_bib55","first-page":"230","article-title":"Topoisomerase II\u03b1, rather than II\u03b2, is a promising target in development of anti-cancer drugs","volume":"6","author":"Chen","year":"2012","journal-title":"Drug Discov. Ther."},{"issue":"26","key":"10.1016\/j.leukres.2023.107020_bib56","doi-asserted-by":"crossref","first-page":"11014","DOI":"10.1073\/pnas.0704002104","article-title":"Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies","volume":"104","author":"Azarova","year":"2007","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"1\u20133","key":"10.1016\/j.leukres.2023.107020_bib57","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/S0167-4781(98)00139-0","article-title":"Secondary leukemias induced by topoisomerase-targeted drugs","volume":"1400","author":"Felix","year":"1998","journal-title":"Biochim. Et. Biophys. Acta (BBA)-Gene Struct. Expr."},{"issue":"1","key":"10.1016\/j.leukres.2023.107020_bib58","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0145-2126(92)90102-D","article-title":"Radiotherapy-and chemotherapy-induced myelodysplasia and acute myeloid leukemia. A review","volume":"16","author":"Pedersen-Bjergaard","year":"1992","journal-title":"Leuk. Res."},{"issue":"9","key":"10.1016\/j.leukres.2023.107020_bib59","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1002\/gcc.20685","article-title":"Rearrangements of the MLL gene are influenced by DNA secondary structure, potentially mediated by topoisomerase II binding","volume":"48","author":"Le","year":"2009","journal-title":"Genes, Chromosomes Cancer"},{"issue":"9\u201310","key":"10.1016\/j.leukres.2023.107020_bib60","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.dnarep.2006.05.031","article-title":"Topoisomerase II and the etiology of chromosomal translocations","volume":"5","author":"Felix","year":"2006","journal-title":"DNA Repair"},{"issue":"1","key":"10.1016\/j.leukres.2023.107020_bib61","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/ng765","article-title":"MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia","volume":"30","author":"Armstrong","year":"2002","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.leukres.2023.107020_bib62","doi-asserted-by":"crossref","first-page":"242","DOI":"10.5045\/br.2016.51.4.242","article-title":"Therapy-related myeloid neoplasms in children and adolescents","volume":"51","author":"Cho","year":"2016","journal-title":"Blood Res."},{"issue":"5824","key":"10.1016\/j.leukres.2023.107020_bib63","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1126\/science.1139851","article-title":"Modeling the initiation and progression of human acute leukemia in mice","volume":"316","author":"Barab\u00e9","year":"2007","journal-title":"Science"},{"issue":"7104","key":"10.1016\/j.leukres.2023.107020_bib64","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/nature04980","article-title":"Transformation from committed progenitor to leukaemia stem cell initiated by MLL\u2013AF9","volume":"442","author":"Krivtsov","year":"2006","journal-title":"Nature"},{"issue":"7540","key":"10.1016\/j.leukres.2023.107020_bib65","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nature13968","article-title":"Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia","volume":"518","author":"Wong","year":"2015","journal-title":"Nature"},{"issue":"10","key":"10.1016\/j.leukres.2023.107020_bib66","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41568-020-0290-x","article-title":"A compendium of mutational cancer driver genes","volume":"20","author":"Mart\u00ednez-Jim\u00e9nez","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.leukres.2023.107020_bib67","article-title":"TP53 mutation in therapy-related myeloid neoplasm defines a distinct molecular subtype","author":"Hiwase","year":"2022","journal-title":"Blood"},{"issue":"7728","key":"10.1016\/j.leukres.2023.107020_bib68","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature"},{"issue":"7463","key":"10.1016\/j.leukres.2023.107020_bib69","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.leukres.2023.107020_bib70","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/j.cell.2012.04.024","article-title":"Mutational processes molding the genomes of 21 breast cancers","volume":"149","author":"Nik-Zainal","year":"2012","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.leukres.2023.107020_bib71","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1038\/s41588-019-0525-5","article-title":"The mutational footprints of cancer therapies","volume":"51","author":"Pich","year":"2019","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.leukres.2023.107020_bib72","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2019.03.001","article-title":"A compendium of mutational signatures of environmental agents","volume":"177","author":"Kucab","year":"2019","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.leukres.2023.107020_bib73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/gm541","article-title":"Mutation signatures of carcinogen exposure: genome-wide detection and new opportunities for cancer prevention","volume":"6","author":"Poon","year":"2014","journal-title":"Genome Med."},{"issue":"203","key":"10.1016\/j.leukres.2023.107020_bib74","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.2002373","article-title":"A method to separate nuclear, cytosolic, and membrane-associated signaling molecules in cultured cells","volume":"4","author":"Liu","year":"2011","journal-title":"Sci. Signal."},{"key":"10.1016\/j.leukres.2023.107020_bib75","article-title":"Genetic and chemotherapeutic causes of germline hypermutation","author":"Kaplanis","year":"2021","journal-title":"bioRxiv"},{"issue":"8","key":"10.1016\/j.leukres.2023.107020_bib76","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41375-021-01293-3","article-title":"The mutagenic impact of melphalan in multiple myeloma","volume":"35","author":"Maura","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.leukres.2023.107020_bib77","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1182\/blood.2019002220","article-title":"Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia","volume":"135","author":"Li","year":"2020","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2023.107020_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-10882-x","article-title":"Engineering transkingdom signalling in plants to control gene expression in rhizosphere bacteria","volume":"10","author":"Geddes","year":"2019","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.leukres.2023.107020_bib79","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/s41588-021-00874-3","article-title":"Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer","volume":"53","author":"Kocakavuk","year":"2021","journal-title":"Nat. Genet."},{"issue":"8","key":"10.1016\/j.leukres.2023.107020_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2021.03.012","article-title":"Patient-derived organoids model cervical tissue dynamics and viral oncogenesis in cervical cancer","volume":"28","author":"L\u00f5hmussaar","year":"2021","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.leukres.2023.107020_bib81","doi-asserted-by":"crossref","unstructured":"B. Diamond, B. Ziccheddu, K. Maclachlan, J. Taylor, E. Boyle, J.A. Ossa, J. Jahn, M. Affer, T.M. Totiger, D. Coffey, 2022. Chemotherapy Signatures Map Evolution of Therapy-Related Myeloid Neoplasms, bioRxiv (2022).","DOI":"10.1101\/2022.04.26.489507"},{"issue":"1","key":"10.1016\/j.leukres.2023.107020_bib82","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat. Commun."},{"key":"10.1016\/j.leukres.2023.107020_bib83","doi-asserted-by":"crossref","first-page":"6997","DOI":"10.1038\/ncomms7997","article-title":"APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma","volume":"6","author":"Walker","year":"2015","journal-title":"Nat. Commun."},{"issue":"13","key":"10.1016\/j.leukres.2023.107020_bib84","first-page":"1735","article-title":"Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma","volume":"128","author":"Weinhold","year":"2016","journal-title":"Blood, J. Am. Soc. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2023.107020_bib85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-018-05058-y","article-title":"Genomic patterns of progression in smoldering multiple myeloma","volume":"9","author":"Bolli","year":"2018","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.leukres.2023.107020_bib86","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-11680-1","article-title":"Genomic landscape and chronological reconstruction of driver events in multiple myeloma","volume":"10","author":"Maura","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.leukres.2023.107020_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-15740-9","article-title":"Timing the initiation of multiple myeloma","volume":"11","author":"Rustad","year":"2020","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.leukres.2023.107020_bib88","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/bloodadvances.2019000779","article-title":"Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma","volume":"4","author":"Ziccheddu","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2023.107020_bib89","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2020-139014","article-title":"High-dose melphalan significantly increases mutational burden in multiple myeloma cells at relapse: results from a randomized study in multiple myeloma","volume":"136","author":"Samur","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107020_bib90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-141611","article-title":"Comprehensive comparison of early relapse and end-stage relapsed refractory multiple myeloma","volume":"136","author":"Poos","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107020_bib91","unstructured":"N. Giesen, N. Paramasivam, U.H. Toprak, D. Huebschmann, J. Xu, S. Uhrig, M. Samur, S. B\u00e4hr, M. Fr\u00f6hlich, S.S. Mughal, 2020. Comprehensive genomic analysis of refractory multiple myeloma reveals a complex mutational landscape associated with drug resistance and novel therapeutic vulnerabilities, Haematologica (2020)."},{"issue":"1","key":"10.1016\/j.leukres.2023.107020_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-32145-y","article-title":"The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states","volume":"13","author":"Rasche","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.leukres.2023.107020_bib93","first-page":"1","article-title":"Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence","author":"Misund","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2023.107020_bib94","article-title":"Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed\/refractory myeloma","author":"Ansari-Pour","year":"2022","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.leukres.2023.107020_bib95","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1182\/bloodadvances.2017008227","article-title":"Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis","volume":"1","author":"Boddu","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.leukres.2023.107020_bib96","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2020.106367","article-title":"Comparison of induction strategies and responses for acute myeloid leukemia patients after resistance to hypomethylating agents for antecedent myeloid malignancy","volume":"93","author":"Talati","year":"2020","journal-title":"Leuk. Res."},{"issue":"1","key":"10.1016\/j.leukres.2023.107020_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-022-01229-z","article-title":"Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure","volume":"15","author":"Short","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.leukres.2023.107020_bib98","doi-asserted-by":"crossref","DOI":"10.1158\/2159-8290.CD-22-0120","article-title":"Elevated mutational age in blood of children treated for cancer contributes to therapy-related myeloid neoplasms","author":"Bertrums","year":"2022","journal-title":"Cancer Discov."},{"issue":"4","key":"10.1016\/j.leukres.2023.107020_bib99","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/modpathol.2014.153","article-title":"High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome","volume":"28","author":"Cleven","year":"2015","journal-title":"Mod. Pathol."},{"issue":"7","key":"10.1016\/j.leukres.2023.107020_bib100","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.44","article-title":"Fanconi anemia gene variants in therapy-related myeloid neoplasms","volume":"5","author":"Voso","year":"2015","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.leukres.2023.107020_bib101","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S1470-2045(16)30627-1","article-title":"Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study","volume":"18","author":"Gillis","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.leukres.2023.107020_bib102","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.cancergen.2018.02.006","article-title":"Mutation analysis of therapy-related myeloid neoplasms","volume":"222","author":"Nishiyama","year":"2018","journal-title":"Cancer Genet."},{"issue":"16","key":"10.1016\/j.leukres.2023.107020_bib103","first-page":"1846","article-title":"Early detection and evolution of preleukemic clones in therapy-related myeloid neoplasms following autologous SCT, Blood","volume":"131","author":"Berger","year":"2018","journal-title":"J. Am. Soc. Hematol."},{"key":"10.1016\/j.leukres.2023.107020_bib104","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2019-128665","article-title":"Comprehensive genomic profiling of pediatric therapy-related myeloid neoplasms identifies Mecom dysregulation to be associated with poor outcome","volume":"134","author":"Schwartz","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.leukres.2023.107020_bib105","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1038\/s41375-019-0479-8","article-title":"The mutational burden of therapy-related myeloid neoplasms is similar to primary myelodysplastic syndrome but has a distinctive distribution","volume":"33","author":"Singhal","year":"2019","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.leukres.2023.107020_bib106","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2019.219352","article-title":"Genomics of therapy-related myeloid neoplasms","volume":"105","author":"Kuzmanovic","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.leukres.2023.107020_bib107","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-021-21255-8","article-title":"The acquisition of molecular drivers in pediatric therapy-related myeloid neoplasms","volume":"12","author":"Schwartz","year":"2021","journal-title":"Nat. Commun."},{"issue":"21","key":"10.1016\/j.leukres.2023.107020_bib108","doi-asserted-by":"crossref","first-page":"2992","DOI":"10.1182\/blood.2020010150","article-title":"Clonal hematopoiesis and therapy-related myeloid neoplasms following neuroblastoma treatment","volume":"137","author":"Coorens","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2023.107020_bib109","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.18129","article-title":"Clonal haematopoiesis as a risk factor for therapy\u2010related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo\u2010(immuno) therapy","author":"Voso","year":"2022","journal-title":"Br. J. Haematol."},{"issue":"5","key":"10.1016\/j.leukres.2023.107020_bib110","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/s41379-021-00958-9","article-title":"Therapy-related myeloid neoplasms with different latencies: a detailed clinicopathologic analysis","volume":"35","author":"Liu","year":"2022","journal-title":"Mod. Pathol."},{"issue":"20","key":"10.1016\/j.leukres.2023.107020_bib111","first-page":"4140","article-title":"Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy","volume":"5","author":"Patel","year":"2021","journal-title":"Blood Adv."},{"issue":"3","key":"10.1016\/j.leukres.2023.107020_bib112","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1080\/17843286.2021.1943232","article-title":"Next generation sequencing in therapy-related myeloid neoplasms compared to de novo myeloid neoplasms","volume":"77","author":"Claerhout","year":"2022","journal-title":"Acta Clin. Belg."},{"issue":"7","key":"10.1016\/j.leukres.2023.107020_bib113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00703-8","article-title":"Therapy-related clonal cytopenia as a precursor to therapy-related myeloid neoplasms","volume":"12","author":"Shah","year":"2022","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.leukres.2023.107020_bib114","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0027-5107(99)00202-X","article-title":"Somatic mutations and aging: a re-evaluation","volume":"447","author":"Vijg","year":"2000","journal-title":"Mutat. Res. \/Fundam. Mol. Mech. Mutagen."},{"issue":"6255","key":"10.1016\/j.leukres.2023.107020_bib115","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1126\/science.aab4082","article-title":"Somatic mutation in cancer and normal cells","volume":"349","author":"Martincorena","year":"2015","journal-title":"Science"},{"issue":"7278","key":"10.1016\/j.leukres.2023.107020_bib116","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nature08658","article-title":"A comprehensive catalogue of somatic mutations from a human cancer genome","volume":"463","author":"Pleasance","year":"2010","journal-title":"Nature"},{"issue":"6127","key":"10.1016\/j.leukres.2023.107020_bib117","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"issue":"28","key":"10.1016\/j.leukres.2023.107020_bib118","doi-asserted-by":"crossref","first-page":"24627","DOI":"10.18632\/oncotarget.5685","article-title":"Age-related somatic mutations in the cancer genome","volume":"6","author":"Milholland","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.leukres.2023.107020_bib119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13073-019-0648-4","article-title":"Somatic mutation and clonal expansions in human tissues","volume":"11","author":"Martincorena","year":"2019","journal-title":"Genome Med."},{"issue":"6","key":"10.1016\/j.leukres.2023.107020_bib120","first-page":"753","article-title":"DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions, blood","volume":"130","author":"Buscarlet","year":"2017","journal-title":"J. Am. Soc. Hematol."},{"key":"10.1016\/j.leukres.2023.107020_bib121","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1146\/annurev-pathmechdis-012419-032544","article-title":"Cardiovascular disease, aging, and clonal hematopoiesis","volume":"15","author":"Evans","year":"2020","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.leukres.2023.107020_bib122","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.exphem.2019.12.005","article-title":"Environmental influences on clonal hematopoiesis","volume":"83","author":"King","year":"2020","journal-title":"Exp. Hematol."},{"issue":"1","key":"10.1016\/j.leukres.2023.107020_bib123","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms100","article-title":"Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis","volume":"12","author":"Gao","year":"2021","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.leukres.2023.107020_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2018.10.004","article-title":"PPM1D mutations drive clonal hematopoiesis in response to cytotoxic chemotherapy","volume":"23","author":"Hsu","year":"2018","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.leukres.2023.107020_bib125","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.109956","article-title":"The role of PPM1D in cancer and advances in studies of its inhibitors","volume":"125","author":"Deng","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.leukres.2023.107020_bib126","doi-asserted-by":"crossref","first-page":"343","DOI":"10.3389\/fphar.2020.00343","article-title":"The drug-resistance mechanisms of five platinum-based antitumor agents","volume":"11","author":"Zhou","year":"2020","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.leukres.2023.107020_bib127","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021014956","article-title":"Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms","author":"Sperling","year":"2022","journal-title":"Blood"},{"issue":"7559","key":"10.1016\/j.leukres.2023.107020_bib128","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1\u03b1 in del (5q) MDS","volume":"523","author":"Kr\u00f6nke","year":"2015","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.leukres.2023.107020_bib129","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccr.2014.08.001","article-title":"Role of casein kinase 1A1 in the biology and targeted therapy of del (5q) MDS","volume":"26","author":"Schneider","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2023.107020_bib130","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet therapy, transplantation, and maintenance until progression in myeloma","author":"Richardson","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.leukres.2023.107020_bib131","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late events after treatment with CD19-targeted chimeric antigen receptor modified T cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"issue":"1","key":"10.1016\/j.leukres.2023.107020_bib132","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.annonc.2020.10.478","article-title":"Side-effect management of chimeric antigen receptor (CAR) T-cell therapy","volume":"32","author":"Schubert","year":"2021","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2023.107020_bib133","first-page":"360","article-title":"Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy, Blood","volume":"128","author":"Bhoj","year":"2016","journal-title":"J. Am. Soc. Hematol."},{"issue":"9","key":"10.1016\/j.leukres.2023.107020_bib134","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1038\/s41591-022-01998-7","article-title":"CAR Treg cells: prime suspects in therapeutic resistance","volume":"28","author":"Saini","year":"2022","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.leukres.2023.107020_bib135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-022-00707-4","article-title":"Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma","volume":"12","author":"Alkhateeb","year":"2022","journal-title":"Blood Cancer J."},{"issue":"7","key":"10.1016\/j.leukres.2023.107020_bib136","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1182\/bloodadvances.2020003857","article-title":"Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma","volume":"5","author":"Parmar","year":"2021","journal-title":"Blood Adv."},{"issue":"8","key":"10.1016\/j.leukres.2023.107020_bib137","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1158\/0008-5472.CAN-12-3542","article-title":"Chemotherapy alters monocyte differentiation to favor generation of cancer-supporting M2 macrophages in the tumor microenvironmenteffect of chemotherapy on tumor microenvironment","volume":"73","author":"Dijkgraaf","year":"2013","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.leukres.2023.107020_bib138","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.stem.2016.04.016","article-title":"In vivo tracking of human hematopoiesis reveals patterns of clonal dynamics during early and steady-state reconstitution phases","volume":"19","author":"Biasco","year":"2016","journal-title":"Cell Stem Cell"},{"issue":"7522","key":"10.1016\/j.leukres.2023.107020_bib139","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/nature13824","article-title":"Clonal dynamics of native haematopoiesis","volume":"514","author":"Sun","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2023.107020_bib140","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1289\/ehp.824321","article-title":"Chemotherapy-induced immunosuppression","volume":"43","author":"Rasmussen","year":"1982","journal-title":"Environ. Health Perspect."},{"issue":"suppl_5","key":"10.1016\/j.leukres.2023.107020_bib141","doi-asserted-by":"crossref","first-page":"S360","DOI":"10.1093\/cid\/ciu592","article-title":"Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies","volume":"59","author":"Morrison","year":"2014","journal-title":"Clin. Infect. Dis."},{"issue":"22","key":"10.1016\/j.leukres.2023.107020_bib142","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJM197111252852201","article-title":"Chemotherapy, immunocompetence, immunosuppression and prognosis in acute leukemia","volume":"285","author":"Hersh","year":"1971","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2023.107020_bib143","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.2147\/OTT.S60114","article-title":"Chemotherapy-enhanced inflammation may lead to the failure of therapy and metastasis","volume":"7","author":"Vyas","year":"2014","journal-title":"OncoTargets Ther."},{"issue":"1","key":"10.1016\/j.leukres.2023.107020_bib144","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/sj.cdd.4402255","article-title":"Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all","volume":"15","author":"van der Most","year":"2008","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.leukres.2023.107020_bib145","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.bbi.2014.02.010","article-title":"Epigenetic changes associated with inflammation in breast cancer patients treated with chemotherapy","volume":"38","author":"Smith","year":"2014","journal-title":"Brain Behav. Immun."},{"issue":"3","key":"10.1016\/j.leukres.2023.107020_bib146","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ygyno.2022.08.021","article-title":"Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma","volume":"167","author":"O'Malley","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.leukres.2023.107020_bib147","article-title":"Mutant PPM1D-and TP53-Driven hematopoiesis populates the hematopoietic compartment in response to peptide receptor radionuclide therapy","volume":"6","author":"Singh","year":"2022","journal-title":"JCO Precis. Oncol."},{"issue":"3","key":"10.1016\/j.leukres.2023.107020_bib148","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1158\/2643-3230.BCD-20-0132","article-title":"Revealing the impact of structural variants in multiple myeloma","volume":"1","author":"Rustad","year":"2020","journal-title":"Blood Cancer Discov."},{"issue":"23","key":"10.1016\/j.leukres.2023.107020_bib149","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1182\/bloodadvances.2019000731","article-title":"Stem cell mutations can be detected in myeloma patients years before onset of secondary leukemias","volume":"3","author":"Sridharan","year":"2019","journal-title":"Blood Adv."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262300005X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014521262300005X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T01:03:54Z","timestamp":1758935034000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014521262300005X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":149,"alternative-id":["S014521262300005X"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107020","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapy-selected clonal hematopoiesis and its role in myeloid neoplasms","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2023.107020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107020"}}